Almirall, S.A. (ALMRY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for joining us for today's quarterly earnings update and review of Almiral's first quarter financial results of 2025. As always, we are sharing the slides we are using today in the investor section of our website at almiral.com. Please move to slide number two. Let me remind you that the information presented in this call contains forward-looking statements, which involve known and unknown risks. uncertainties, and other factors that may cause actual results to materially differ from what we are sharing today. Please move to slide number three. Presenting today are Carlos Gallardo, Chairman and Chief Executive Officer, Mike McKellan, Chief Financial Officer, and Carl Sigabar, Chief Scientific Officer. Carlos will start with the business highlights covering the first quarter of 2025. followed by an update especially on biologics as the key growth drivers on our medical dermatology portfolio. Carl will provide you with an R&D status update regarding our pipeline. And Mike will then talk you through the financials before Carlos concludes the presentation. And we open for questions. I will hand over to Carlos Gallardo, our chairman and CEO. Please move to slide number five. Thank you, Pablo. We are delighted to share with you that we have started the year with continued strong business performance that is very much aligned with the long-term trajectory of sustained growth we have outlined for Foral Mirai recently. Therefore, we are pleased to confirm our full year guidance for 2025, our mid-term outlook and pictures projections. This represents another quarter in the right direction in our ambition to transform the life of pay Euclid delivered a strong peak sales during the first quarter of 2025, benefiting from the dynamic German market, but also from initial ...